Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device RefluxStop®, a treatment field with 1 billion sufferers, announces the publication of RefluxStop’s extraordinary 5-year clinical data for food passageway-related outcomes in the prestigious journal, Surgical Endoscopy (https://link.springer.com/article/10.1007/s00464-025-11818-x), an official journal of SAGES (American Gastrointestinal and Endoscopic Surgeons) and EAES (European Association For Endoscopic Surgery).

Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces the submission of the third and final module of the RefluxStop® pre-market approval (PMA) application with the US Food and Drug Administration (FDA), along with responses to the second module.

Implantica AG (publ.), a MedTech company at the forefront of treatment for acid reflux with its unique device RefluxStop™, a treatment field with 1 billion sufferers, announces the successful first UK National Users Meeting bringing together 21 top anti-reflux experts in UK last week. Surgeons exchanged their real-world experiences and delved into the positive National Institute for Health and Care Excellence (NICE) recommendations on using RefluxStop in NHS hospitals, opening a vast opportunity for RefluxStop procedures in patients with poor motility, representing up to 40-50%[1] of the acid reflux (GERD/GORD) sufferers.

Implantica AG (publ.), a MedTech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces the publication of a new independent real-world study (https://pubmed.ncbi.nlm.nih.gov/40317294/) from Switzerland demonstrating RefluxStop™’s consistent long-term outcomes irrespective of large or small hiatal hernia size before surgery, proving it to be a favorable option for patients also with large hernia.

Implantica AG (publ.), providing the unique device RefluxStop™ for the treatment of acid reflux, announces that the world-renowned National Institute for Healthcare Excellence (NICE (https://www.nice.org.uk/)) payer advisory agency for NHS public hospitals in the UK has published positive Interventional Procedures Guidance (IPG) recommendations on the RefluxStop™ procedure, wherein GORD/GERD patients with Ineffective Oesophageal Motility (IOM/IEM) are allowed to be operated with RefluxStop procedure in the public healthcare system, following its guidelines and special arrangements.

Implantica AG (publ.) reports successful pre-launch activities in the U.S., pending FDA approval, with European real-world clinical evidence generating much interest from U.S. surgeons.

Today, May 15, 2025, the annual general meeting (the “AGM”) of Implantica AG (publ) was held in Ruggell, Liechtenstein. The general meeting resolved to adopt all of the board of directors’ resolution proposals. A summary of the resolutions adopted at the general meeting is set out below.

Global expansion of RefluxStop™

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces another prestigious Center of Excellence in Spain to offer RefluxStop™, Hospital Universitario Central de Asturias in Oviedo, Spain.

Implantica AG (publ) invites investors to a presentation of the first quarter 2025 at 15:00 CEST on May 9. The interim report for the first quarter will be published at 8:00 a.m. CEST on the same day.